Spectaire (SPEC) Competitors

SPEC vs. TBIO, THMO, HTGMQ, OLITW, and PRENW

Should you buy Spectaire stock or one of its competitors? MarketBeat compares Spectaire with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectaire include Telesis Bio (TBIO), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), and Prenetics Global (PRENW). These companies are all part of the "measuring and control equipment" industry.

How does Spectaire compare to Telesis Bio?

Spectaire (NASDAQ:SPEC) and Telesis Bio (NASDAQ:TBIO) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

26.5% of Spectaire shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 25.4% of Spectaire shares are owned by company insiders. Comparatively, 24.5% of Telesis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled Telesis Bio'saverage media sentiment score.

Company	Overall Sentiment
Spectaire	Neutral
Telesis Bio	Neutral

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectaire	N/A	-81.22%	304.57%
Telesis Bio	-336.59%	N/A	-61.89%

Spectaire has a beta of -6.91, meaning that its share price is 791% less volatile than the broader market. Comparatively, Telesis Bio has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

Spectaire has higher earnings, but lower revenue than Telesis Bio. Telesis Bio is trading at a lower price-to-earnings ratio than Spectaire, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectaire	N/A	N/A	$8.95M	-$0.30	N/A
Telesis Bio	$225.09M	0.00	-$47.72M	-$20.52	N/A

Summary

Spectaire and Telesis Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Spectaire compare to ThermoGenesis?

ThermoGenesis (NASDAQ:THMO) and Spectaire (NASDAQ:SPEC) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 26.5% of Spectaire shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 25.4% of Spectaire shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spectaire has lower revenue, but higher earnings than ThermoGenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ThermoGenesis	$9.61M	0.00	-$17.98M	-$5.14	N/A
Spectaire	N/A	N/A	$8.95M	-$0.30	N/A

In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Spectaire'saverage media sentiment score.

Company	Overall Sentiment
ThermoGenesis	Neutral
Spectaire	Neutral

ThermoGenesis has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Spectaire has a beta of -6.91, indicating that its share price is 791% less volatile than the broader market.

ThermoGenesis' return on equity of 0.00% beat Spectaire's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ThermoGenesis	N/A	N/A	N/A
Spectaire	N/A	-81.22%	304.57%

Summary

ThermoGenesis beats Spectaire on 5 of the 9 factors compared between the two stocks.

How does Spectaire compare to HTG Molecular Diagnostics?

Spectaire (NASDAQ:SPEC) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Spectaire has a beta of -6.91, meaning that its stock price is 791% less volatile than the broader market. Comparatively, HTG Molecular Diagnostics has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market.

HTG Molecular Diagnostics' return on equity of 0.00% beat Spectaire's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectaire	N/A	-81.22%	304.57%
HTG Molecular Diagnostics	N/A	N/A	N/A

Spectaire has higher earnings, but lower revenue than HTG Molecular Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectaire	N/A	N/A	$8.95M	-$0.30	N/A
HTG Molecular Diagnostics	$6.37M	0.00	-$21.59M	-$2.28	N/A

26.5% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.

Company	Overall Sentiment
Spectaire	Neutral
HTG Molecular Diagnostics	Neutral

Summary

Spectaire beats HTG Molecular Diagnostics on 5 of the 9 factors compared between the two stocks.

How does Spectaire compare to OmniLit Acquisition?

Spectaire (NASDAQ:SPEC) and OmniLit Acquisition (NASDAQ:OLITW) are both measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

OmniLit Acquisition's return on equity of 0.00% beat Spectaire's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectaire	N/A	-81.22%	304.57%
OmniLit Acquisition	N/A	N/A	N/A

26.5% of Spectaire shares are held by institutional investors. 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled OmniLit Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Spectaire	Neutral
OmniLit Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectaire	N/A	N/A	$8.95M	-$0.30	N/A
OmniLit Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Spectaire beats OmniLit Acquisition on 3 of the 4 factors compared between the two stocks.

How does Spectaire compare to Prenetics Global?

Spectaire (NASDAQ:SPEC) and Prenetics Global (NASDAQ:PRENW) are both measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Spectaire has higher earnings, but lower revenue than Prenetics Global.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectaire	N/A	N/A	$8.95M	-$0.30	N/A
Prenetics Global	$92.39M	N/A	N/A	N/A	N/A

Prenetics Global's return on equity of 0.00% beat Spectaire's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectaire	N/A	-81.22%	304.57%
Prenetics Global	N/A	N/A	N/A

26.5% of Spectaire shares are owned by institutional investors. 25.4% of Spectaire shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Spectaire's average media sentiment score of 0.00 equaled Prenetics Global'saverage media sentiment score.

Company	Overall Sentiment
Spectaire	Neutral
Prenetics Global	Neutral

Summary

Spectaire beats Prenetics Global on 3 of the 5 factors compared between the two stocks.

Get Spectaire News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

SPEC vs. The Competition

Export

Metric	Spectaire	Measuring & controlling devices Industry	Computer Sector	NASDAQ Exchange
Market Cap	$9K	$142.61M	$39.37B	$12.34B
Dividend Yield	N/A	11.01%	3.19%	5.28%
P/E Ratio	0.00	6.27	79.18	25.66
Price / Sales	N/A	8.28	628.47	86.31
Price / Cash	N/A	8.38	48.72	56.67
Price / Book	N/A	1.34	10.54	7.14
Net Income	$8.95M	$6.26M	$1.07B	$335.98M

Spectaire Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPEC Spectaire	N/A	N/A	N/A	N/A	$9K	N/A	N/A	8
TBIO Telesis Bio	N/A	$0.00 flat	N/A	N/A	$2K	$225.09M	N/A	200
THMO ThermoGenesis	N/A	N/A	N/A	N/A	$1K	$9.61M	N/A	40
HTGMQ HTG Molecular Diagnostics	N/A	N/A	N/A	N/A	$0.00	$6.37M	N/A	90
OLITW OmniLit Acquisition	N/A	$1.30 +20.4%	N/A	+2,306.9%	$0.00	N/A	N/A	3	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPEC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spectaire (SPEC) Competitors

SPEC vs. TBIO, THMO, HTGMQ, OLITW, and PRENW

How does Spectaire compare to Telesis Bio?

Summary

How does Spectaire compare to ThermoGenesis?

Summary

How does Spectaire compare to HTG Molecular Diagnostics?

Summary

How does Spectaire compare to OmniLit Acquisition?

Summary

How does Spectaire compare to Prenetics Global?

Summary

New MarketBeat Followers Over Time

SPEC vs. The Competition

Spectaire Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spectaire (SPEC) Competitors

SPEC vs. TBIO, THMO, HTGMQ, OLITW, and PRENW

How does Spectaire compare to Telesis Bio?

Do insiders & institutionals have more ownership in SPEC or TBIO?

Does the media refer more to SPEC or TBIO?

Is SPEC or TBIO more profitable?

Which has more volatility and risk, SPEC or TBIO?

Which has stronger earnings and valuation, SPEC or TBIO?

Summary

How does Spectaire compare to ThermoGenesis?

Do institutionals & insiders believe in THMO or SPEC?

Which has stronger valuation and earnings, THMO or SPEC?

Does the media prefer THMO or SPEC?

Which has more volatility and risk, THMO or SPEC?

Is THMO or SPEC more profitable?

Summary

How does Spectaire compare to HTG Molecular Diagnostics?

Which has more volatility & risk, SPEC or HTGMQ?

Is SPEC or HTGMQ more profitable?

Which has stronger earnings & valuation, SPEC or HTGMQ?

Do insiders and institutionals believe in SPEC or HTGMQ?

Does the media favor SPEC or HTGMQ?

Summary

How does Spectaire compare to OmniLit Acquisition?

Is SPEC or OLITW more profitable?

Do insiders and institutionals believe in SPEC or OLITW?

Does the media prefer SPEC or OLITW?

Which has stronger earnings and valuation, SPEC or OLITW?

Summary

How does Spectaire compare to Prenetics Global?

Which has preferable valuation & earnings, SPEC or PRENW?

Is SPEC or PRENW more profitable?

Do institutionals & insiders hold more shares of SPEC or PRENW?

Does the media prefer SPEC or PRENW?

Summary

New MarketBeat Followers Over Time

SPEC vs. The Competition

Spectaire Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools